•Leadership watch: Saunders exits B+L, ZEISS names Vision Care CEO, and other executive moves•Roche reports phase 3 data on steroid-free therapy for UME management•Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery•FDA clears Surrozen's IND for DME therapy•Empire Forum co-chairs preview retina's new investor-industry meeting•Leadership watch: Saunders exits B+L, ZEISS names Vision Care CEO, and other executive moves•Roche reports phase 3 data on steroid-free therapy for UME management•Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery•FDA clears Surrozen's IND for DME therapy•Empire Forum co-chairs preview retina's new investor-industry meeting
HEADLINES
FEATURED
Subcutaneous version of satralizumab-mwge can be administered by a patient or caregiver following training from an HCP.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
